EGFR (Luc) HEK293 Reporter Cell
描述（Description）
The Human EGF R (Luc) HEK293 Reporter Cell was engineered to not only express STAT3 signaling response element, but also express the receptor full length human EGF R (Gene ID: 1956). When stimulated with human EGF protein, the EGF/EGF R interaction drives STAT3-mediated luminescence. Inhibition of EGF binding to EGF R by either anti-EGF or anti-EGF R antibodies results in a decrease in luminescence.
應用說明（Application）
1. Screen for anti-human EGF R or anti-human EGF neutralizing antibody.
2. Screen for human EGF R small molecule inhibitor
生長特性（Growth Properties）
Adherent
篩選標記（Selection Marker）
Hygromycin (40 μg/mL) + Puromycin (2 μg/mL)
培養(yǎng)基（Culture Medium）
DMEM medium + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲（Storage）
Frozen in liquid nitrogen.
支原體檢測（Mycoplasma Testing）
Negative
無菌檢測（Sterility Testing）
Negative
使用說明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). The aberrant activity of EGFR has shown to play a key role in the development and growth of tumor cells, where it is involved in numerous cellular responses including proliferation and apoptosis.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關鍵字： EGFR報告細胞系;EGFR報告細胞株;EGFR細胞系;EGFR細胞株;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。